Glucose

Glucose is a sterile solution for injection containing glucose monohydrate as the sole active ingredient. It is supplied in a liquid form intended for intravenous administration. The product is manufactured for the European market and is used as an energy substrate to raise blood glucose levels when rapid correction is required. As a parenteral carbohydrate, it supports cellular metabolism in clinical settings in hospital environments and emergency care.

Glucose injection is indicated for the rapid treatment of low blood sugar and for providing an immediate source of carbohydrate in various clinical situations.

- Acute hypoglycemia in patients receiving insulin or oral hypoglycemic agents. - Energy support during surgery or anesthesia when oral intake is not possible. - Management of electrolyte imbalances that require carbohydrate supplementation. - Treatment of hyperkalemia as part of a regimen to shift potassium intracellularly. - Nutritional support in patients unable to tolerate enteral feeding.

Intravenous glucose may cause a range of reactions, most of which are mild and transient, while rare serious events can occur.

Common: - Transient rise in blood glucose levels that typically normalize within hours. - Local discomfort, warmth, or irritation at the infusion site during administration. - Nausea, mild vomiting, or abdominal discomfort shortly after infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis, dehydration, and electrolyte loss. - Allergic reactions ranging from skin rash and itching to full‑body anaphylaxis. - Pulmonary edema or cardiac arrhythmias in patients with underlying heart or fluid‑balance disorders.

When using intravenous glucose, clinicians should observe several precautions to minimize risks and ensure safe administration.

- Verify patient’s blood glucose level before infusion to avoid overt hyperglycemia. - Adjust infusion rate in patients with renal or cardiac insufficiency to prevent fluid overload. - Monitor electrolytes, especially potassium, during and after administration. - Use aseptic technique to reduce risk of infection at the injection site. - Avoid rapid bolus administration in neonates and infants. - Assess for history of hypersensitivity to glucose solutions before use.

Glucose injection can interact with other medications or clinical conditions, requiring careful consideration of concurrent therapies.

Avoid: - Co‑administration with high‑dose insulin without monitoring, which may precipitate severe hypoglycemia. - Simultaneous infusion of hypertonic dextrose solutions, which can cause excessive hyperglycemia.

Use with caution: - Concurrent use of potassium‑sparing diuretics, as rapid glucose infusion may shift potassium intracellularly. - Administration with beta‑adrenergic agonists, which can augment glucose release and affect blood sugar control. - Patients receiving total parenteral nutrition, requiring adjustment of carbohydrate content.